MET and prostate carcinoma: In addition, overexpression of ErbB2 diminished the binding of c-Met to plexin B1, suggesting that in breast cancer cells and in prostate cancer cells, ErbB2 and c-Met are competing for plexin B1 binding, which largely determines the cellular outcome of Sema4D signalling.